Generative AI’s First Real-World Health Test
A new university-led study puts generative AI head-to-head with traditional research teams in a high-stakes medical data challenge, with surprising results.
UK-US Zero Tariff Deal on Pharmaceuticals
The US and UK have reached a zero-tariff deal on pharmaceuticals, but the real impact can be felt across investment, innovation, and public health.
Global Drugmakers Rush for U.S. Presence
If you’ve been watching the news, you might have noticed that big pharma isn’t just waiting around, they’re making moves to stay ahead of potential tariffs. Here’s what investors should know.
Pharma Stocks Split as Trump Unveils 100% Drug Tariff
Trump’s 100% tariff on foreign-made branded drugs has shaken markets, with analysts warning the impact won’t be evenly felt.
Buy, Sell, or Hold: Hims & Hers Stock Surges 64%
The past six months have been a windfall for Hims & Hers Health’s shareholders as the stock surged 64%. Is now the right time to buy HIMS? Or is this rally more about investor enthusiasm than fundamentals?
This Biotech’s Phase 3 Results Could Be a Game-Changer for Investors
The next few weeks for aTyr Pharma will reveal a great deal about this company’s future. aTyr Pharma is set to transform treatment for pulmonary sarcoidosis and unlock blockbuster potential. Is the stock a good investment right now? Let’s find out.
Early-Stage Biotech Gets $1.3B Boost From New Investor
Frazier Life Sciences has secured $1.3 billion for early-stage biotech investing, making it the third major firm in recent months to raise significant capital. In a market showing both resilience and selectivity, the fund highlights where opportunity and investor conviction remains strong.
‘Unusually Cautious’: Biotech Dealmakers Hit the Brakes
After a quiet period for biotech M&A, dealmakers started 2025 with renewed optimism. Many expected a rebound in billion-dollar transactions, bolstered by early momentum like Johnson & Johnson’s $14.6 billion acquisition of neuroscience biotech Intra-Cellular Therapies, announced in January. Enthusiasm has since faded, with political instability and market swings cooling appetites and deepening the divide […]
GSK Q1 Strength Signals Tariff Resilience
British pharma heavyweight GSK reports a strong start to 2025 with earnings exceeding forecasts and reaffirms its growth outlook—positioning itself as a stable force even as potential U.S. pharmaceutical tariffs loom.
Trade War Hits Pharma: U.S.-EU Dispute Threatens Drug Prices
The pharmaceutical industry is on high alert as U.S.-EU trade tensions threaten to put blockbuster drugs in the tariff crosshairs.
English 
German